|
Q2 FY2026
As of Jun 30, 2026
|
Q1 FY2026
As of Mar 31, 2026
|
Q4 FY2025
As of Dec 31, 2025
|
Q3 FY2025
As of Sep 30, 2025
|
Q2 FY2025
As of Jun 30, 2025
|
Q1 FY2025
As of Mar 31, 2025
|
Q4 FY2024
As of Dec 31, 2024
|
Q3 FY2024
As of Sep 30, 2024
|
Q2 FY2024
As of Jun 30, 2024
|
Q1 FY2024
As of Mar 31, 2024
|
Q4 FY2023
As of Dec 31, 2023
|
Q3 FY2023
As of Sep 30, 2023
|
Q2 FY2023
As of Jun 30, 2023
|
Q1 FY2023
As of Mar 31, 2023
|
Q4 FY2022
As of Dec 31, 2022
|
Q3 FY2022
As of Sep 30, 2022
|
Q2 FY2022
As of Jun 30, 2022
|
Q1 FY2022
As of Mar 31, 2022
|
Q4 FY2021
As of Dec 31, 2021
|
Q3 FY2021
As of Sep 30, 2021
|
|
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Assets | ||||||||||||||||||||
| Current assets: | ||||||||||||||||||||
| Cash | ||||||||||||||||||||
| Grant receivable | ||||||||||||||||||||
| Reimbursement right | ||||||||||||||||||||
| Due from related party | ||||||||||||||||||||
| Prepaid expenses and other current assets | ||||||||||||||||||||
| Total current assets | ||||||||||||||||||||
| Property and equipment, net of depreciation | ||||||||||||||||||||
| Goodwill | ||||||||||||||||||||
| Intangible assets | ||||||||||||||||||||
| Right-of-use asset, net of amortization | ||||||||||||||||||||
| Security deposit | ||||||||||||||||||||
| Deferred offering costs | ||||||||||||||||||||
| Total assets | ||||||||||||||||||||
| Liabilities, Series A Non-Voting Convertible Preferred Stock, Series B Non-Voting Convertible Preferred Stock, and Stockholders' Equity (Deficit) | ||||||||||||||||||||
| Current liabilities: | ||||||||||||||||||||
| Accounts payable and accrued expenses | ||||||||||||||||||||
| Deferred grant income | ||||||||||||||||||||
| Short-term lease liability | ||||||||||||||||||||
| Notes payable - convertible, at fair value | ||||||||||||||||||||
| Total current liabilities | ||||||||||||||||||||
| Long-term liabilities: | ||||||||||||||||||||
| Warrant liability | ||||||||||||||||||||
| Series C warrants | ||||||||||||||||||||
| Series D warrants | ||||||||||||||||||||
| Long-term lease liability | ||||||||||||||||||||
| Contingent consideration | ||||||||||||||||||||
| Deferred tax liability | ||||||||||||||||||||
| Long-term liabilities | ||||||||||||||||||||
| Total liabilities | ||||||||||||||||||||
| Series A Non-Voting Convertible Preferred Stock - $0.0001 par value per share; 1,242.0718 shares authorized at June 30, 2026, and December 31, 2025; 1,212.1822 shares issued and outstanding at June 30, 2026, and December 31, 2025 | ||||||||||||||||||||
| Series A Preferred Stock | ||||||||||||||||||||
| Series B Preferred Stock | ||||||||||||||||||||
| Stockholders' equity (deficit): | ||||||||||||||||||||
| Non-Voting Convertible Preferred Stock | ||||||||||||||||||||
| Common stock - $0.0001 par value per share; 290,000,000 shares authorized at June 30, 2026, and December 31, 2025; 1,011,595 and 916,968 shares issued and outstanding at June 30, 2026, and December 31, 2025, respectively | ||||||||||||||||||||
| Additional paid-in capital | ||||||||||||||||||||
| Accumulated deficit | ||||||||||||||||||||
| Total stockholders' equity (deficit) | ||||||||||||||||||||
| Total liabilities, Series A Non-Voting Convertible Preferred Stock, Series B Non-Voting Convertible Preferred Stock, and stockholders' equity (deficit) | ||||||||||||||||||||
Loading...
